OPM announces its 2026 half-year financial results and provides an update on its clinical developments and financial position

OPM announces its 2026 half-year financial results and provides an update on its clinical developments and financial position

Dijon, France, October 22, 2026, 6:00 p.m. CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2026, ended June 30, 2026.